APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pleurodynia Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pleurodynia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025198 pages

Choose your research edition.

Industry ResearchPleurodynia Treatment Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Pleurodynia Treatment Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Pleurodynia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pleurodynia Treatment Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Pleurodynia Treatment Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Pleurodynia Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pleurodynia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pleurodynia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pleurodynia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pleurodynia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pleurodynia Treatment include Takeda Pharmaceuticals, Teva Pharmaceutical lndustries, Sanofi, Johnson & Johnson, Novartis, Merck & Co., Eli Lilly and Company, Pfizer and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pleurodynia Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pleurodynia Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pleurodynia Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pleurodynia Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Pleurodynia Treatment Segment by Company

Takeda Pharmaceuticals

Teva Pharmaceutical lndustries

Sanofi

Johnson & Johnson

Novartis

Merck & Co.

Eli Lilly and Company

Pfizer

GlaxoSmithKline

Bayer

Bristol Myers Squibb

Amgen

AbbVie

AstraZeneca

Roche Holding AG

Gilead Sciences

Daiichi Sankyo

Boehringer Ingelheim

Astellas Pharma.

Pleurodynia Treatment Segment by Type

Anti-Inflammatory Drugs

Analgesics

Other

Pleurodynia Treatment Segment by Application

Hospital

Clinic

Other

Pleurodynia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pleurodynia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pleurodynia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pleurodynia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pleurodynia Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pleurodynia Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pleurodynia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pleurodynia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pleurodynia Treatment Industry Trends Table 2. Pleurodynia Treatment Industry Drivers Table 3. Pleurodynia Treatment Industry Opportunities and Challenges Table 4. Pleurodynia Treatment Industry Restraints Table 5. Global Pleurodynia Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pleurodynia Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pleurodynia Treatment Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Pleurodynia Treatment Sales Market Share by Manufacturers Table 9. Global Pleurodynia Treatment Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Pleurodynia Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pleurodynia Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pleurodynia Treatment Manufacturers, Product Type & Application Table 13. Global Pleurodynia Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pleurodynia Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Anti-Inflammatory Drugs Table 17. Major Manufacturers of Analgesics Table 18. Major Manufacturers of Other Table 19. Global Pleurodynia Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Pleurodynia Treatment Sales by Type (2021-2026) & (k units) Table 21. Global Pleurodynia Treatment Sales by Type (2027-2032) & (k units) Table 22. Global Pleurodynia Treatment Sales Market Share by Type (2021-2026) Table 23. Global Pleurodynia Treatment Sales Market Share by Type (2027-2032) Table 24. Global Pleurodynia Treatment Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Pleurodynia Treatment Revenue by Type (2021-2026) & (k units) Table 26. Global Pleurodynia Treatment Revenue by Type (2027-2032) & (k units) Table 27. Global Pleurodynia Treatment Revenue Market Share by Type (2021-2026) Table 28. Global Pleurodynia Treatment Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Clinic Table 31. Major Manufacturers of Other Table 32. Global Pleurodynia Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Pleurodynia Treatment Sales by Application (2021-2026) & (k units) Table 34. Global Pleurodynia Treatment Sales by Application (2027-2032) & (k units) Table 35. Global Pleurodynia Treatment Sales Market Share by Application (2021-2026) Table 36. Global Pleurodynia Treatment Sales Market Share by Application (2027-2032) Table 37. Global Pleurodynia Treatment Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Pleurodynia Treatment Revenue by Application (2021-2026) & (k units) Table 39. Global Pleurodynia Treatment Revenue by Application (2027-2032) & (k units) Table 40. Global Pleurodynia Treatment Revenue Market Share by Application (2021-2026) Table 41. Global Pleurodynia Treatment Revenue Market Share by Application (2027-2032) Table 42. Global Pleurodynia Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Pleurodynia Treatment Sales by Region (2021-2026) & (k units) Table 44. Global Pleurodynia Treatment Sales Market Share by Region (2021-2026) Table 45. Global Pleurodynia Treatment Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Pleurodynia Treatment Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Pleurodynia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Pleurodynia Treatment Sales by Country (2021-2026) & (k units) Table 49. North America Pleurodynia Treatment Sales by Country (2027-2032) & (k units) Table 50. Europe Pleurodynia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Pleurodynia Treatment Sales by Country (2021-2026) & (k units) Table 52. Europe Pleurodynia Treatment Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Pleurodynia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Pleurodynia Treatment Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Pleurodynia Treatment Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Pleurodynia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Pleurodynia Treatment Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Pleurodynia Treatment Sales by Country (2027-2032) & (k units) Table 59. Global Pleurodynia Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Pleurodynia Treatment Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Pleurodynia Treatment Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Pleurodynia Treatment Revenue Market Share by Region (2021-2026) Table 63. Global Pleurodynia Treatment Revenue Market Share by Region (2027-2032) Table 64. Takeda Pharmaceuticals Company Information Table 65. Takeda Pharmaceuticals Business Overview Table 66. Takeda Pharmaceuticals Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Takeda Pharmaceuticals Pleurodynia Treatment Product Portfolio Table 68. Takeda Pharmaceuticals Recent Development Table 69. Teva Pharmaceutical lndustries Company Information Table 70. Teva Pharmaceutical lndustries Business Overview Table 71. Teva Pharmaceutical lndustries Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Teva Pharmaceutical lndustries Pleurodynia Treatment Product Portfolio Table 73. Teva Pharmaceutical lndustries Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sanofi Pleurodynia Treatment Product Portfolio Table 78. Sanofi Recent Development Table 79. Johnson & Johnson Company Information Table 80. Johnson & Johnson Business Overview Table 81. Johnson & Johnson Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Johnson & Johnson Pleurodynia Treatment Product Portfolio Table 83. Johnson & Johnson Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Novartis Pleurodynia Treatment Product Portfolio Table 88. Novartis Recent Development Table 89. Merck & Co. Company Information Table 90. Merck & Co. Business Overview Table 91. Merck & Co. Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Merck & Co. Pleurodynia Treatment Product Portfolio Table 93. Merck & Co. Recent Development Table 94. Eli Lilly and Company Company Information Table 95. Eli Lilly and Company Business Overview Table 96. Eli Lilly and Company Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Eli Lilly and Company Pleurodynia Treatment Product Portfolio Table 98. Eli Lilly and Company Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Pfizer Pleurodynia Treatment Product Portfolio Table 103. Pfizer Recent Development Table 104. GlaxoSmithKline Company Information Table 105. GlaxoSmithKline Business Overview Table 106. GlaxoSmithKline Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. GlaxoSmithKline Pleurodynia Treatment Product Portfolio Table 108. GlaxoSmithKline Recent Development Table 109. Bayer Company Information Table 110. Bayer Business Overview Table 111. Bayer Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Bayer Pleurodynia Treatment Product Portfolio Table 113. Bayer Recent Development Table 114. Bristol Myers Squibb Company Information Table 115. Bristol Myers Squibb Business Overview Table 116. Bristol Myers Squibb Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Bristol Myers Squibb Pleurodynia Treatment Product Portfolio Table 118. Bristol Myers Squibb Recent Development Table 119. Amgen Company Information Table 120. Amgen Business Overview Table 121. Amgen Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Amgen Pleurodynia Treatment Product Portfolio Table 123. Amgen Recent Development Table 124. AbbVie Company Information Table 125. AbbVie Business Overview Table 126. AbbVie Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. AbbVie Pleurodynia Treatment Product Portfolio Table 128. AbbVie Recent Development Table 129. AstraZeneca Company Information Table 130. AstraZeneca Business Overview Table 131. AstraZeneca Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. AstraZeneca Pleurodynia Treatment Product Portfolio Table 133. AstraZeneca Recent Development Table 134. Roche Holding AG Company Information Table 135. Roche Holding AG Business Overview Table 136. Roche Holding AG Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Roche Holding AG Pleurodynia Treatment Product Portfolio Table 138. Roche Holding AG Recent Development Table 139. Gilead Sciences Company Information Table 140. Gilead Sciences Business Overview Table 141. Gilead Sciences Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Gilead Sciences Pleurodynia Treatment Product Portfolio Table 143. Gilead Sciences Recent Development Table 144. Daiichi Sankyo Company Information Table 145. Daiichi Sankyo Business Overview Table 146. Daiichi Sankyo Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Daiichi Sankyo Pleurodynia Treatment Product Portfolio Table 148. Daiichi Sankyo Recent Development Table 149. Boehringer Ingelheim Company Information Table 150. Boehringer Ingelheim Business Overview Table 151. Boehringer Ingelheim Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Boehringer Ingelheim Pleurodynia Treatment Product Portfolio Table 153. Boehringer Ingelheim Recent Development Table 154. Astellas Pharma. Company Information Table 155. Astellas Pharma. Business Overview Table 156. Astellas Pharma. Pleurodynia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 157. Astellas Pharma. Pleurodynia Treatment Product Portfolio Table 158. Astellas Pharma. Recent Development Table 159. Key Raw Materials Table 160. Raw Materials Key Suppliers Table 161. Pleurodynia Treatment Distributors List Table 162. Pleurodynia Treatment Customers List Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Pleurodynia Treatment Product Image Figure 2. Global Pleurodynia Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pleurodynia Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Pleurodynia Treatment Sales (2021-2032) & (k units) Figure 5. Global Pleurodynia Treatment Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pleurodynia Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Anti-Inflammatory Drugs Image Figure 9. Analgesics Image Figure 10. Other Image Figure 11. Global Pleurodynia Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Pleurodynia Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Pleurodynia Treatment Sales Market Share by Type (2021-2032) Figure 14. Global Pleurodynia Treatment Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Pleurodynia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Pleurodynia Treatment Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Pleurodynia Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Pleurodynia Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Pleurodynia Treatment Sales Market Share by Application (2021-2032) Figure 23. Global Pleurodynia Treatment Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Pleurodynia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Pleurodynia Treatment Revenue Market Share by Application (2021-2032) Figure 26. North America Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Pleurodynia Treatment Sales Market Share by Country (2021-2032) Figure 28. U.S. Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Pleurodynia Treatment Sales Market Share by Country (2021-2032) Figure 33. Germany Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Pleurodynia Treatment Sales Market Share by Country (2021-2032) Figure 40. China Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Pleurodynia Treatment Sales Market Share by Country (2021-2032) Figure 48. Brazil Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Pleurodynia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Pleurodynia Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Pleurodynia Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Pleurodynia Treatment Revenue (2021-2032) & (US$ Million) Figure 59. North America Pleurodynia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Pleurodynia Treatment Revenue (2021-2032) & (US$ Million) Figure 61. Europe Pleurodynia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Pleurodynia Treatment Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Pleurodynia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Pleurodynia Treatment Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Pleurodynia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Pleurodynia Treatment Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Pleurodynia Treatment Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-Inflammatory Drugs
  • Analgesics
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical lndustries
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co.
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • Bristol Myers Squibb
  • Amgen
  • AbbVie
  • AstraZeneca
  • Roche Holding AG
  • Gilead Sciences
  • Daiichi Sankyo
  • Boehringer Ingelheim
  • Astellas Pharma.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pleurodynia Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pleurodynia Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pleurodynia Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pleurodynia Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pleurodynia Treatment Market Dynamics
  1. 2.1 Pleurodynia Treatment Industry Trends
  2. 2.2 Pleurodynia Treatment Industry Drivers
  3. 2.3 Pleurodynia Treatment Industry Opportunities and Challenges
  4. 2.4 Pleurodynia Treatment Industry Restraints
3 Pleurodynia Treatment Market by Manufacturers
  1. 3.1 Global Pleurodynia Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pleurodynia Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pleurodynia Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pleurodynia Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pleurodynia Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pleurodynia Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Pleurodynia Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pleurodynia Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pleurodynia Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pleurodynia Treatment Tier 1, Tier 2, and Tier 3
4 Pleurodynia Treatment Market by Type
  1. 4.1 Pleurodynia Treatment Type Introduction
  2. 4.1.1 Anti-Inflammatory Drugs
  3. 4.1.2 Analgesics
  4. 4.1.3 Other
  5. 4.2 Global Pleurodynia Treatment Sales by Type
  6. 4.2.1 Global Pleurodynia Treatment Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pleurodynia Treatment Sales by Type (2021-2032)
  8. 4.2.3 Global Pleurodynia Treatment Sales Market Share by Type (2021-2032)
  9. 4.3 Global Pleurodynia Treatment Revenue by Type
  10. 4.3.1 Global Pleurodynia Treatment Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pleurodynia Treatment Revenue by Type (2021-2032)
  12. 4.3.3 Global Pleurodynia Treatment Revenue Market Share by Type (2021-2032)
5 Pleurodynia Treatment Market by Application
  1. 5.1 Pleurodynia Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Pleurodynia Treatment Sales by Application
  6. 5.2.1 Global Pleurodynia Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pleurodynia Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global Pleurodynia Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pleurodynia Treatment Revenue by Application
  10. 5.3.1 Global Pleurodynia Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pleurodynia Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global Pleurodynia Treatment Revenue Market Share by Application (2021-2032)
6 Global Pleurodynia Treatment Sales by Region
  1. 6.1 Global Pleurodynia Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pleurodynia Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Pleurodynia Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Pleurodynia Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pleurodynia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pleurodynia Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pleurodynia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pleurodynia Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pleurodynia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pleurodynia Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pleurodynia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pleurodynia Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pleurodynia Treatment Revenue by Region
  1. 7.1 Global Pleurodynia Treatment Revenue by Region
  2. 7.1.1 Global Pleurodynia Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pleurodynia Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Pleurodynia Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Pleurodynia Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pleurodynia Treatment Revenue (2021-2032)
  8. 7.2.2 North America Pleurodynia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pleurodynia Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Pleurodynia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pleurodynia Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pleurodynia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pleurodynia Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pleurodynia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Pleurodynia Treatment Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Teva Pharmaceutical lndustries
  8. 8.2.1 Teva Pharmaceutical lndustries Company Information
  9. 8.2.2 Teva Pharmaceutical lndustries Business Overview
  10. 8.2.3 Teva Pharmaceutical lndustries Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical lndustries Pleurodynia Treatment Product Portfolio
  12. 8.2.5 Teva Pharmaceutical lndustries Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Pleurodynia Treatment Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Pleurodynia Treatment Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Pleurodynia Treatment Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck & Co.
  32. 8.6.1 Merck & Co. Company Information
  33. 8.6.2 Merck & Co. Business Overview
  34. 8.6.3 Merck & Co. Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co. Pleurodynia Treatment Product Portfolio
  36. 8.6.5 Merck & Co. Recent Developments
  37. 8.7 Eli Lilly and Company
  38. 8.7.1 Eli Lilly and Company Company Information
  39. 8.7.2 Eli Lilly and Company Business Overview
  40. 8.7.3 Eli Lilly and Company Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly and Company Pleurodynia Treatment Product Portfolio
  42. 8.7.5 Eli Lilly and Company Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Pleurodynia Treatment Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 GlaxoSmithKline
  50. 8.9.1 GlaxoSmithKline Company Information
  51. 8.9.2 GlaxoSmithKline Business Overview
  52. 8.9.3 GlaxoSmithKline Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Pleurodynia Treatment Product Portfolio
  54. 8.9.5 GlaxoSmithKline Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Pleurodynia Treatment Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Bristol Myers Squibb
  62. 8.11.1 Bristol Myers Squibb Company Information
  63. 8.11.2 Bristol Myers Squibb Business Overview
  64. 8.11.3 Bristol Myers Squibb Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol Myers Squibb Pleurodynia Treatment Product Portfolio
  66. 8.11.5 Bristol Myers Squibb Recent Developments
  67. 8.12 Amgen
  68. 8.12.1 Amgen Company Information
  69. 8.12.2 Amgen Business Overview
  70. 8.12.3 Amgen Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amgen Pleurodynia Treatment Product Portfolio
  72. 8.12.5 Amgen Recent Developments
  73. 8.13 AbbVie
  74. 8.13.1 AbbVie Company Information
  75. 8.13.2 AbbVie Business Overview
  76. 8.13.3 AbbVie Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AbbVie Pleurodynia Treatment Product Portfolio
  78. 8.13.5 AbbVie Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Pleurodynia Treatment Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Roche Holding AG
  86. 8.15.1 Roche Holding AG Company Information
  87. 8.15.2 Roche Holding AG Business Overview
  88. 8.15.3 Roche Holding AG Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Roche Holding AG Pleurodynia Treatment Product Portfolio
  90. 8.15.5 Roche Holding AG Recent Developments
  91. 8.16 Gilead Sciences
  92. 8.16.1 Gilead Sciences Company Information
  93. 8.16.2 Gilead Sciences Business Overview
  94. 8.16.3 Gilead Sciences Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Gilead Sciences Pleurodynia Treatment Product Portfolio
  96. 8.16.5 Gilead Sciences Recent Developments
  97. 8.17 Daiichi Sankyo
  98. 8.17.1 Daiichi Sankyo Company Information
  99. 8.17.2 Daiichi Sankyo Business Overview
  100. 8.17.3 Daiichi Sankyo Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Daiichi Sankyo Pleurodynia Treatment Product Portfolio
  102. 8.17.5 Daiichi Sankyo Recent Developments
  103. 8.18 Boehringer Ingelheim
  104. 8.18.1 Boehringer Ingelheim Company Information
  105. 8.18.2 Boehringer Ingelheim Business Overview
  106. 8.18.3 Boehringer Ingelheim Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Pleurodynia Treatment Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Recent Developments
  109. 8.19 Astellas Pharma.
  110. 8.19.1 Astellas Pharma. Company Information
  111. 8.19.2 Astellas Pharma. Business Overview
  112. 8.19.3 Astellas Pharma. Pleurodynia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Astellas Pharma. Pleurodynia Treatment Product Portfolio
  114. 8.19.5 Astellas Pharma. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pleurodynia Treatment Value Chain Analysis
  2. 9.1.1 Pleurodynia Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pleurodynia Treatment Production Mode & Process
  6. 9.2 Pleurodynia Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pleurodynia Treatment Distributors
  9. 9.2.3 Pleurodynia Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst